Home
Donation
Contents
A CLL Primer
Current Articles
Topics Alert
Project Alpha
Your Charts
Feedback
Reference
Textbooks
Search Tools
About Us

 

 

Clinical Trials

 

Closure of FluCam 106 Trial

October 21, 2004

New Clinical Trial in the Works to Test Important Combination Therapy

Letter from Dr. Andrew Sandler of Berlex

Dear Friends at CLL Topics: 

Berlex has decided to close the study FluCam 106, A Phase II Study Comparing Fludarabine/Campath to Fludarabine/Rituximab. This decision was reached as a result of low enrollment on the current study and strong feedback that indicated that the scientific question asked continues to be of interest. Comments from many of the investigators indicated that the stringent  inclusion / exclusion criteria, rigorous schedule of events and overall protocol complexity made it difficult to enroll patients. Therefore, based on this feedback, we will be developing a new study which asks a similar scientific question, however the overall complexity of the study design will be greatly reduced - a benefit to both the investigator and the patient. Berlex will continue to keep CLL Topics apprised of the progress on this new study and the sites that will be participating.  We expect the new trial to be up and running by March of 2005. 

Best regards,

Andrew S. Sandler, M.D.
Associate Director
Berlex Oncology

Details of the FluCam 106 clinical trial as originally constituted are provided in our article titled FluCam 106.



Clinical Trials

Print

Home

Contents

Current Articles